Teva Pharmaceutical Industries Ltd (TEVA.TA)
6 Mar 2014
|Market Cap (Mil.):||₪166,961.59|
|Shares Outstanding (Mil.):||948.42|
LONDON, Feb 21 - European regulators recommended the approval of a clutch of drugs to treat respiratory diseases on Friday, including two from GlaxoSmithKline and another from Teva Pharmaceuticals.
* Teva, Ranbaxy to pay $150,000 each to settle with New York State
Feb 18 - The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition.
Feb 18 - Generic drugmaker Actavis Plc said it would acquire specialty pharmaceuticals company Forest Laboratories Inc in a cash and stock deal valued at about $25 billion.
Feb 16 - Israeli drugmaker Teva Pharmaceutical Industries Ltd became the largest single stock holding for Soros Fund Management LLC, the family office of billionaire investor George Soros, in the fourth quarter, according to a Feb. 14 filing with the U.S. Securities and Exchange Commission.
Feb 10 - Teva Pharmaceutical Industries Ltd said on Monday that the U.S. Department of Justice has opened an investigation into the marketing and promotion of multiple sclerosis drug Copaxone and Parkinson's Disease treatment Azilect.
TEL AVIV - Teva Pharmaceutical Industries' fourth quarter earnings rose 8 percent, beating analysts' estimates, on stronger sales from specialty medicines and U.S. generic drugs.
TEL AVIV, Feb 6 - Teva Pharmaceutical Industries' fourth quarter earnings rose 8 percent, beating analysts' estimates, on stronger sales from specialty medicines and U.S. generic drugs.
Feb 6 - Teva Pharmaceutical Industries acting CEO Eyal Desheh says:
TEL AVIV - Teva Pharmaceutical Industries reported on Thursday higher quarterly earnings that beat analysts' estimates on higher sales from U.S. generic drugs and global specialty medicines.
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (TEVA). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Teva Pharmaceutical Industries Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: New Constructs, LLC
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of TEVA PHARMACEUTICAL INDS-ADR including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.